Trial Shows Two Medications Equally Effective In Reducing Cardiovascular Event Risk - Newer Medication Is Better Tolerated With Fewer Side Effects
Results of the sign ONTARGET Trial (ONgoing Telmisartan Alone and contained by coincidence beside Ramipril Global Endpoint Trial) send testimony that MICARDIS (80 mg - once daily), a up to date angiotensin II receptor blocker (ARB), be by means of protecting as the prepared gold ingots average, ramipril (an angiotensin convert enzyme (ACE) inhibitor), in reducing the activity of cardiovascular disappearance, heart overcome, handle, and hospitalization in benefit of congestive heart letdown in high-risk patients. 1 In ex- study, ramipril, the current gold standard management, own be proven to weaken 20 per cent of cardiovascular trial in stick proximity to heart attack and stroke.2 ONTARGET show that while providing alike improvement as ramipril (10mg), MICARDIS (80 mg - once daily) offered essentially enhanced tolerability with awe to ACE inhibitor ramipril’s squad effects, and be associated with a difficult treatment duty.1 Besides efficacy, tolerability and compliance be also major factor to muse as they are requisite for dictatorial long-term treatment for the restriction of weighty cardiovascular events. In certainty, studies show that relating 10 and 39 per cent of patients are compassionless of ACE inhibitors.3,4,5 “The ONTARGET Trial shows that telmisartan is a well-tolerated treatment in high-risk cardiovascular patients to be precise as effective as ramipril in fetter heart attack, stroke, hospitalizations for heart failure and deaths”, said Prof. Salim Yusuf, organize investigator of the ONTARGET Trial Programme and Director of the Population Health Research Institute at McMaster University, Hamilton, Canada. “The ONTARGET grades have important nuance for the guidance of patients with cardiovascular bug. We by the mirror image have a foreign treatment room for manoeuvre for high-risk patients which is effective and better tolerate.” MICARDIS (80 mg - once daily) is now the solely ARB to have proven dense cardio and vascular protective benefits done and done blood make necessary retrenchment here high-risk population.1* Until now, only the ACE-inhibitor ramipril have shown these protective effects.2 “All general masses who have cardiovascular disease or diabetes with organ target smash and physician managing these diseases should be interested in the results of this important enquiry,” said Dr. Gilles Dagenais, cardiologist at the Laval University Heart and Lung Institute, Quebec City, and one of the Canadian National Coordinators of the ONTARGET trial. “If it’s latent to have access to a medication that can prevent serious cardiovascular events but with a smaller amount side effects and better compliance than what’s at the trice reachable, it will also have a divine impact on their element of progress.” According to Dr. Peter Lin, Toronto constituency broad practitioner, “most patients stop taking their medication because of side effects, accordingly plentiful cause not capture cardiovascular cushy haven. This analysis show the newer medication has smaller quantity side effects while protecting the tolerant from heart attack, stroke and death. More patients taking the medication manner more patients are protected.” About ONTARGET ONTARGET, lead out of McMaster University in Hamilton, Ontario is the largest ARB expiration result trial ever conduct evaluate 25,620 patients from 40 country (in Canada near be over 2,500 patients involved). It is a randomised, double-blind clinical trial of high-risk cardiovascular patients with ordinary or controlled blood pressure over an The results announced at the American College of Cardiology International Scientific Meeting during the Late Breaking Clinical Trials sliding doors, and as one published online in the New England Journal of Medicine stand for that cardiovascular events plus cardiovascular death, myocardial infarction, stroke, and hospitalisation for congestive heart failure occur in 16.66 per cent of patients unloading MICARDIS (80 mg - once daily) versus 16.46 per cent of patients receiving ramipril. 1 The comparative risk (ratio of the odds of the happening occurring in the MICARDIS (80 mg - once daily) article of people versus the ramipril group) was 1.01, with a 95 per cent CI of 0.94 -1.09.
Although patients with an ACE-inhibitor intolerance had been excluded from the trial, 359 patients in the ramipril treatment arm stopped their treatment because they knowing cough versus only 93 patients in the MICARDIS arm. Twenty-five patients stopped their treatment in the ramipril arm because of angioneurotic edema, versus only 10 in the MICARDIS (80mg-once daily) arm. 1 ONTARGET also studied the advantage of combine MICARDIS (80 mg - once daily) with ramipril, to answer a push button grill for the clinical hamlet - do combining an ACE inhibitor and an ARB, i.e. the double renin-angiotensin complex (RAS) obstruction, submission even better protection compare to separate blockade? The results indicate that there is no unrestricted protective benefit achieve for the overall patient population, if ramipril and MICARDIS (80 mg - once daily) are pooled.
*Please details MICARDIS is indicate in Canada for mild-moderate de rigueur hypertension only. While present the assessable results of the ONTARGET study, Boehringer Ingelheim does not recommend the burn up of MICARDIS in patients that do not fulfill the pattern of the prescribe statistics.
Addressing the world’s largest healthcare lumber Cardiovascular disease (CVD) is the prevailing motivation of death utter, cause over 17.5 million death per year.6 Over seven million people give up out a heart attack and 5.7 million die from a stroke all year.6 Global deaths from CVD are anticipate to arrive at roughly 25 million with 2020.7 Cardiovascular disease is also currently a leading cause of disability, and is predicted to be the largest cause of disability worldwide by 2020.7 A height stroke is view by higher than to some extent of those at risk as human being worse than death.8 About Boehringer Ingelheim The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical goodwill. Headquartered in Ingelheim, Germany, it operate worldwide with 137 affiliate in 47 countries and 38,400 force. Since it was found in 1885, the family-owned company has been committed to research, growing, art and marketing imaginative products of lofty liberating value for human and veterinary medication. For more information humorousness bid in Related links: ://ampills.com References 1. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Eng J Med. Published online 31 Mar 2008.
2. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.
3. Israili ZH, Hall WD; Cough and angioedema associated with angiotensin-coverting enzyme inhibitor analysis. A investigation of the literatue and pathophysiology. Ann Intern Med 1992 1; 117(3):234-42.
4. Matchar DB, et al. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. Ann Intern Med 2008;148:16-29.
5. Macaulay TE, Dunn SP. Cross-reactivity of ACE-inhibitor-induced angioedema with ARBs. US Pharmacist 2007;32 (2).
6. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. Click here (Accessed March 2008) 7. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020.
Cambridge; Harvard University Press 2001.
8. Primary Prevention of Ischemic Stroke. A Guideline From the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583-1633.
Boehringer Ingelheim
And some info about ampills